Peer Exchange

EP. 1: Biosimilars in Oncology: Addressing Awareness

EP. 2: Current State of Biosimilars: Approval, Availability, and Efficacy

EP. 3: Biosimilars in Oncology: Equivalency and Cost

EP. 4: Are Biosimilar Costs a Factor for Patients?

EP. 5: Biosimilars: Addressing Roadblocks to Market Adoption

EP. 6: Switching to Available Biosimilars in Oncology

EP. 7: Determining Biosimilars' Role in the Formulary

EP. 8: Market-Access Considerations for Biosimilars in Oncology

EP. 9: Where Do Biosimilars Fit in to the Treatment Landscape?

EP. 10: Multiple Biosimilars for a Single-Reference Biologic

EP. 11: Strategies for Incorporating Biosimilars Into Care Plans

EP. 12: Incorporating Biosimilars in Oncology: Working Collaboratively

EP. 13: Economic Impact of Biosimilars in Oncology

EP. 14: Biosimilars in Oncology: Long-Term Financial Benefit

EP. 15: Competition in the Biosimilar Marketplace

EP. 16: Biosimilars in Oncology: Future Directions

EP. 1: Pfizer's Citizen Petition on Biosimilar Communications

EP. 2: Combating Misinformation and Misconceptions About Biosimilars

EP. 3: Targeted Education for Biosimilar Stakeholders

EP. 4: US Versus EU Education on Biosimilars

EP. 5: The FDA's Approach to Biosimilar Education

EP. 6: Biosimilarity, Manufacturing Changes, and Comparability

EP. 7: Clinicians' Understanding of Manufacturing Changes

EP. 8: The Extrapolation of Indications

EP. 9: Selecting the Most Sensitive Population for Confirmatory Trials

EP. 10: Immunogenicity and Biosimilars

EP. 11: Misconceptions About Interchangeability

EP. 12: Clinical Studies for Biosimilars

EP. 13: The Future of US Biosimilars

EP. 14: The Role of Biosimilars in the US Healthcare System

EP. 15: Allowing the US Biosimilars Market to Flourish

EP. 16: Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars

EP. 17: Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use

EP. 18: Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars

EP. 19: Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars

EP. 20: Madelaine Feldman, MD: Practical Considerations for Biosimilars

EP. 21: Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

EP. 22: Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars

EP. 1: Patient Awareness of Biosimilars and Loyalty to Branded Drugs

EP. 2: Patient Savings From Biosimilars

EP. 3: Barriers to Biosimilars for Oncology Patients

EP. 4: Biosimilars, Payers, and Formulary Changes

EP. 5: The Exceptions Process and its Effect on Patients

EP. 6: Patient Education on Coverage for Biologics and Biosimilars

EP. 7: Alternative Payment Models and Patient Care

EP. 8: The Cost of Biologics and Biosimilars

EP. 9: Rebates and Medicare Part D

EP. 10: CMS' Changes to Reimbursement for Biosimilars

EP. 11: Biosimilars, Private Payers, and Pharmacy-Level Substitution

EP. 12: Patient Assistance Programs and Biosimilars

EP. 13: Manufacturers and the Cost of Biosimilars and Biologics

EP. 14: Diversity in Clinical Trials for Biosimilars

EP. 15: The FDA and Diversity in Clinical Trials

EP. 16: Oncology Biosimilars Making a Difference for Patients

EP. 17: Putting Patients at the Center of the Biosimilar Conversation

EP. 1: Biosimilar Interchangeability and Market Share

EP. 2: Interchangeability and Rheumatology Prescribing Practices

EP. 3: Biosimilars, Interchangeability, and Perceptions of Safety

EP. 4: Global Reference Products in Biosimilar Development

EP. 5: Inspection Reports and Proprietary Information

EP. 6: Reforms at the FDA Level

EP. 7: Biosimilars, Formularies, Contracting, and PBMs

EP. 8: Biosimilar Uptake and Health Plans

EP. 9: CMS and Blended Reimbursement Codes

EP. 10: Healthcare Reform Efforts and the BPCIA

EP. 11: State Laws and Biosimilar Substitution

EP. 12: The PTAB's Role in Biosimilar Patent Disputes

EP. 13: The Need for Clarity After <i>Sandoz v Amgen</i>

EP. 14: Upcoming Patent Litigation in Biosimilars

EP. 15: Challenges Ahead for Biosimilars

EP. 1: Adoption of Biosimilars in the United States and Europe

EP. 2: Delivery Systems and the Acceptance of Biosimilars

EP. 3: Cost and Biosimilar Uptake for Oncology

EP. 4: Biosimilar Prescribing and Cost in Rheumatology

EP. 5: Prescribing Behaviors and Biosimilar Substitution

EP. 6: Chronic Therapy and Switching

EP. 7: Physician Understanding of Biologic Manufacturing

EP. 8: Clinical Trial Design With Biosimilars

EP. 9: Post-Market Pharmacovigilance

EP. 10: Patient Awareness of Biosimilar Products

EP. 11: Payer Intervention and Biosimilar Switching

EP. 12: Extrapolation of Indications in Biosimilars

EP. 13: Cost and Biosimilars in Oncology

EP. 14: Competition and Cost for Biosimilars

EP. 15: Cost, Patient Programs, and Access to Biosimilars

EP. 16: Naming and Coding of Biosimilars

EP. 17: State Legislation on Biosimilars and Substitution

EP. 18: Biosimilars in the Next 5 Years

EP. 1: Knowledge Gaps With Biosimilars

EP. 2: Differences Between Biosimilars and Generic Drugs

EP. 3: Approval Process for Biosimilars

EP. 4: Naming of Biosimilars

EP. 5: Clinical Experience With Biosimilars

EP. 6: Use of Biosimilars in Inflammatory Diseases

EP. 7: Cost and Prescribing Considerations for Biosimilars

EP. 8: Variables Affecting Cost for Biosimilars

EP. 9: Formulary Considerations for Biosimilars

EP. 10: Challenges in Discussing Biosimilars With Patients

EP. 11: Clinician Awareness of Future Biosimilars

EP. 12: The Future of Biosimilars and Managing Inflammatory Diseases

Peer Exchange

Understanding and Improving Access of Biosimilars in Oncology

Stakeholders Summit: Provider Education on Biosimilars

Bringing Oncology Biosimilars to Patients

Regulation, Policy, and Litigation in Biosimilars

Clinical Advances and Challenges With Biosimilars

Clinician and Managed Care Insights on Biosimilars for Inflammatory Diseases